Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?
Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?
复制标题
作者：
NK 细胞针对血液恶性肿瘤的抗肿瘤活性已得到充分证实，许多研究支持其在控制实体瘤生长和转移生成中的作用。然而，肿瘤微环境可能会影响NK细胞功能。正在进行的研究旨在设计新的免疫治疗方案，将基于 NK 细胞的免疫疗法与其他治疗策略相结合，以改善抗肿瘤 NK 细胞反应。在这种情况下，UCB 是成熟 NK 细胞和可在体内和体外产生 NK 细胞的 CD34+ HSPC 的主要来源之一。 UCB 衍生的 NK 细胞是进行体外和临床前分析的宝贵工具，并且已用于多种临床环境，特别是针对血液恶性肿瘤。本综述描述了不同类型的 UCB 衍生 NK 细胞的特征以及扩展它们的体外模型，用于癌症免疫治疗背景下的研究和临床目的。在过去 20 年中，基于自然杀伤 (NK) 细胞的免疫疗法已成为针对各种类型癌症的一种有前途的方法。事实上，NK 细胞通过主要的组织相容性复合物独立的免疫监视，在肿瘤的一线防御中发挥着关键作用。它们在控制白血病复发中的作用已明确确定，此外，肿瘤微环境 (TME) 中 NK 细胞的存在通常与良好的预后相关。然而，也有人观察到，NK 细胞通常很难浸润肿瘤组织，并且在 TME 中，它们的功能可能会受到免疫抑制因素的损害，从而导致抗癌免疫反应失败。目前，研究重点是设计有效的策略来扩增 NK 细胞并增强其细胞毒活性，利用不同的细胞来源，如外周血 (PB)、脐带血 (UCB) 和 NK 细胞系。其中，UCB代表了成熟NK细胞和CD34+造血干细胞和祖细胞（HSPC）的重要来源，作为NK细胞的前体。在这篇综述中，我们总结了肿瘤背景下 UCB 衍生的 NK 细胞活性，回顾了从 UCB 中扩增 NK 细胞的不同体外模型，并讨论了它们在抗肿瘤免疫治疗方案中开发的重要性。
NK cell anti-tumor activity against hematological malignancies is well-established and many studies support their role in the control of solid tumor growth and metastasis generation. However, tumor microenvironment may affect NK cell function. Ongoing studies are aimed to design novel immunotherapeutic protocols to combine NK cell-based immunotherapy with other therapeutic strategies to improve the anti-tumor NK cell response. In this context, UCB is one of the main sources of both mature NK cells and of CD34+ HSPC that can generate NK cells, both in-vivo and in-vitro. UCB-derived NK cells represent a valuable tool to perform in-vitro and preclinical analyses and are already used in several clinical settings, particularly against hematological malignancies. The present review describes the characteristics of different types of UCB-derived NK cells and the in-vitro models to expand them, both for research and clinical purposes in the context of cancer immunotherapy. In the last 20 years, Natural Killer (NK) cell-based immunotherapy has become a promising approach to target various types of cancer. Indeed, NK cells play a pivotal role in the first-line defense against tumors through major histocompatibility complex-independent immunosurveillance. Their role in the control of leukemia relapse has been clearly established and, moreover, the presence of NK cells in the tumor microenvironment (TME) generally correlates with good prognosis. However, it has also been observed that, often, NK cells poorly infiltrate the tumor tissue, and, in TME, their functions may be compromised by immunosuppressive factors that contribute to the failure of anti-cancer immune response. Currently, studies are focused on the design of effective strategies to expand NK cells and enhance their cytotoxic activity, exploiting different cell sources, such as peripheral blood (PB), umbilical cord blood (UCB) and NK cell lines. Among them, UCB represents an important source of mature NK cells and CD34+ Hematopoietic Stem and Progenitor Cells (HSPCs), as precursors of NK cells. In this review, we summarize the UCB-derived NK cell activity in the tumor context, review the different in-vitro models to expand NK cells from UCB, and discuss the importance of their exploitation in anti-tumor immunotherapy protocols.
登录
查看更多内容
影响因子：
28.2
作者：
Cózar B;Greppi M;Carpentier S;Narni-Mancinelli E;Chiossone L;Vivier E
通讯作者：
Vivier E
影响因子：
20.3
作者：
Cooley, S;McCullar, V;Miller, JS
通讯作者：
Miller, JS
影响因子：
4.4
作者：
Campbell, JJ;Qin, SX;Butcher, EC
通讯作者：
Butcher, EC
影响因子：
64.5
作者：
André P;Denis C;Soulas C;Bourbon-Caillet C;Lopez J;Arnoux T;Bléry M;Bonnafous C;Gauthier L;Morel A;Rossi B;Remark R;Breso V;Bonnet E;Habif G;Guia S;Lalanne AI;Hoffmann C;Lantz O;Fayette J;Boyer-Chammard A;Zerbib R;Dodion P;Ghadially H;Jure-Kunkel M;Morel Y;Herbst R;Narni-Mancinelli E;Cohen RB;Vivier E
通讯作者：
Vivier E
影响因子：
10.1
作者：
通讯作者：
--